Long-term Follow-up of Full Macular Translocation for Choroidal Neovascularization

Yamada, Yoshihisa; Miyamura, Noritake; Suzuma, Kiyoshi; Kitaoka, Takashi

doi:10.1016/j.ajo.2009.09.014

Cited by 16 publications

(12 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In one study, Yamada et al 22 reported that the BCVA was not significantly changed at 1 year and significantly worsened after 45 years. These differences from our findings could be because the preoperative BCVA was worse in their patients than ours.…”

Section: Discussionmentioning

confidence: 99%

“…Our results at 12 months are consistent with these findings. Yamada et al 22 reported that the mean BCVA before operation was maintained until the final follow-up in five of five myopic cases after a mean follow-up time of 6.5 years.…”

Section: Discussionmentioning

confidence: 99%

“…Most studies have reported favourable outcomes but for follow-up periods of r2 years after the surgery. 9,11,12,[15][16][17][18][19][20] On the other hand, there are two reports on the visual outcome of macular translocation surgery with follow-up periods of Z3 years, 21,22 and the visual outcomes were reported to be poor in both. However, in these two reports, the visual improvement was not attained even in the first year.…”

Section: Introductionmentioning

confidence: 99%

“…For eyes with a mCNV, the findings Z5 years after macular translocation surgery were presented but the results of only five cases were reported. 22 We have recorded focal electroretinograms from the translocated macular area and found it was significantly better than that before operation at 22 months postoperatively. 18,20 However, the results after longer follow-up periods have not been reported.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Visual function 5 years or more after macular translocation surgery for myopic choroidal neovascularisation and age-related macular degeneration

Takeuchi

Kachi

Iwata

et al. 2011

Eye

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Visual function 5 years or more after macular translocation surgery for myopic choroidal neovascularisation and age-related macular degeneration

Takeuchi

Kachi

Iwata

et al. 2011

Eye

View full text Add to dashboard Cite

“…Controversial results were reported in submacular surgery for myopic CNV [132,133,134] ranging from no change [134] to an improvement of 2 lines in 45% of the eyes [132,135]. Two techniques of macular translocation – limited macular translocation and macular translocation with 360-degree (MT360) retinotomy – have been performed in the last decade also with controversial results [136,137,138,139]. Better results were reported for limited macular translocation than for surgical removal [137] but with a high rate of recurrences.…”

Section: Treatment Of Myopic Cnvmentioning

confidence: 99%

Myopic Maculopathy: A Review

Silva

2012

Ophthalmologica

100

View full text Add to dashboard Cite

Pathological myopia is a major cause of irreversible vision loss and is the fourth to ninth most frequent cause of blindness in the world. Choroidal neovascularization (CNV) secondary to pathological myopia is the leading cause of vision impairment in patients younger than 50 years. New scientific contributions have been made to the understanding of high myopia and associated CNV. New treatments have been used in recent years, and the results are still controversial. This paper is an updated review of pathological myopia – its definition and progression, epidemiology and genetics – and a review of myopic CNV including the natural history, epidemiology, risk factors, pathogenic mechanisms and treatment.

show abstract

The Application of Biomaterials to Tissue Engineering Neural Retina and Retinal Pigment Epithelium

Hunt

Hallam

Chichagova

et al. 2018

Adv Healthcare Materials

View full text Add to dashboard Cite

The prevalence of degenerative retinal disease is ever increasing as life expectancy rises globally. The human retina fails to regenerate and the use of human embryonic stem cells (hESCs) and human-induced pluripotent stem cells (hiPSCs) to engineer retinal tissue is of particular interest due to the limited availability of suitable allogeneic or autologous tissue. Retinal tissue and its development are well characterized, which have resulted in robust assays to assess the development of tissue-engineered retina. Retinal tissue can be generated in vitro from hESCs and hiPSCs without biomaterial scaffolds, but despite advancements, protocols remain slow, expensive, and fail to result in mature functional tissue. Several recent studies have demonstrated the potential of biomaterial scaffolds to enhance generation of hESC/hiPSC-derived retinal tissue, including synthetic polymers, silk, alginate, hyaluronic acid, and extracellular matrix molecules. This review outlines the advances that have been made toward tissue-engineered neural retina and retinal pigment epithelium (RPE) for clinical application in recent years, including the success of clinical trials involving transplantation of cells and tissue to promote retinal repair; and the evidence from in vitro and animal studies that biomaterials can enhance development and integration of retinal tissue.

show abstract

Long-term Follow-up of Full Macular Translocation for Choroidal Neovascularization

Cited by 16 publications

References 20 publications

Visual function 5 years or more after macular translocation surgery for myopic choroidal neovascularisation and age-related macular degeneration

Visual function 5 years or more after macular translocation surgery for myopic choroidal neovascularisation and age-related macular degeneration

Myopic Maculopathy: A Review

The Application of Biomaterials to Tissue Engineering Neural Retina and Retinal Pigment Epithelium

Contact Info

Product

Resources

About